首页> 外文OA文献 >Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

【2h】

Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

机译：遗传诊断特征在表皮生长因子受体（EGFR）中初始治疗失败后的含有EGFR突变的非小细胞肺癌患者中的纯溶酶激酶抑制剂

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yuichiro Takeda; Go Naka; Yoh Yamaguchi; Masao Hashimoto; Manabu Suzuki; Shinyu Izumi; Haruhito Sugiyama;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 第一代酪氨酸激酶抑制剂治疗中发生进展的非小细胞肺癌血浆表皮生长因子受体(EGFR) T790M突变提示了失败部位并预测了临床预后:一项前瞻性观察研究 [J] . Shirong Zhang, Lucheng Zhu, Bing Xia, 癌症（英文版） . 2018,第009期
2. 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究 [J] . Xiangyang Yu, Xuewen Zhang, Zichen Zhang, 癌症（英文版） . 2019,第010期
3. Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [J] . Wen Gao, Jing He, Shi-Dai Jin, OncoTargets and therapy . 2019,第2期

机译：初始表皮生长因子受体酪氨酸激酶抑制剂治疗和EGFR外显子抑制作用的抗T790M突变抗性抗性抗性抗肺癌患者的抗性抗性，抗血疱剂血管生长因子受体酪氨酸激酶激酶抑制剂
4. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations [J] . Makoto Nishio, Haruyasu Murakami, Yuichiro Ohe, Investigational new drugs. . 2019,第6期

机译：I阶段研究Tas-121，第三代表皮生长因子受体（EGFR）酪氨酸激酶抑制剂，患有EGFR突变的非小细胞肺癌患者
5. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109) [J] . Hattori Yoshihiro, Satouchi Miyako, Shimada Temiko, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第2期

机译：一线EGFR酪氨酸激酶抑制剂失败后，具有表皮生长因子受体（EGFR）突变的非鳞状非小细胞肺癌患者中贝伐单抗联合卡铂和紫杉醇的2期研究（HANSHIN Oncology Group 0109 ）
6. Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma [C] . Yeul Hong Kim, Hye Sook Kim, Jae Sook Sung, Molecular Medicine TRI-CON. . 2014

机译：下一代测序对非小细胞肺癌抗蛋白酶激酶抑制剂进行下一代测序检测的低负荷EGFR突变的预测疗效
7. Unanticipated Effects of Tyrosine Kinase Inhibitors on Vitamin D Receptor Expression and Gene Regulation In Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer. [D] . Timberlake, Alexandra F. 2017

机译：酪氨酸激酶抑制剂对表皮生长因子受体突变的非小细胞肺癌中维生素D受体表达和基因调控的意外影响。
8. Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations [O] . Yuichiro Takeda, Go Naka, Yoh Yamaguchi, 2020

机译：遗传诊断特征在表皮生长因子受体（EGFR）中初始治疗失败后的含有EGFR突变的非小细胞肺癌患者中的纯溶酶激酶抑制剂
9. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations [O] . Juanjuan Dong, Sihao Tong, Xianfeng Shi, 2021

机译：促使肽肽前体和神经元特异性烯醇酶预测，非小细胞肺癌患者患有EGFR突变的非小细胞肺癌患者中一线治疗与表皮生长因子受体（EGFR）酪氨酸激酶抑制剂的疗效

Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

著录项

引文网络

相似文献

相关主题

期刊订阅